Summary

The 7 major erectile dysfunction markets reached a value of US$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.9 Billion by 2034, exhibiting a growth rate (CAGR) of 6.53% during 2024-2034.

The erectile dysfunction market has been comprehensively analyzed in IMARC's new report titled "Erectile Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Erectile dysfunction (ED), also known as impotence, refers to the inability to achieve or maintain an erection sufficient for sexual intercourse. ED can have both physical and psychological causes, and the condition can profoundly impact the patient's quality of life and relationships. Atherosclerosis and other diseases that affect blood vessels can impede or restrict blood flow to the penis, leading to erectile dysfunction. In neurological disorders (including multiple sclerosis), nerves that provide impulses to the penis can be damaged because of a stroke, diabetes, or other reasons. Psychological causes, such as stress, depression, a lack of brain stimulation, performance anxiety, etc., can contribute to ED by triggering a decrease in libido. Some of the common symptoms of erectile dysfunction are persistent trouble getting an erection, difficulty maintaining an erection, and reduced sexual desire. The diagnosis typically involves a comprehensive medical evaluation, such as a physical exam, blood tests, and a review of the patient's medical history. In some cases, a specialist may perform additional tests, such as a penile ultrasound, to determine the cause of the ailment. Treatment for erectile dysfunction varies depending on the underlying reason but may involve lifestyle modifications, including eating a nutritious diet, exercising regularly, and quitting smoking. Generally, oral medications are adopted to treat ED. In severe cases, penile implants or vacuum pumps may be advised.

The increasing incidences of several physical and psychological disorders, such as cardiovascular diseases, diabetes, high blood pressure, depression, anxiety, use of certain medications, etc., are primarily driving the global erectile dysfunction market. In addition to this, the rising prevalence of numerous lifestyle factors, including smoking, excessive alcohol consumption, substance abuse, etc., which elevate the risk of ED, is also creating a positive outlook for the market. Moreover, the growing awareness towards erectile dysfunction as a medical condition, which is leading to a greater willingness among men to seek treatment, is further augmenting the global market. Besides this, the emerging popularity of intracavernosal injections for treating ED among patients who do not respond to oral medications is acting as a significant growth-inducing factor. Furthermore, the widespread adoption of penile implants, such as inflatable or malleable devices, which can be surgically inserted into the penis to provide a permanent solution to ED, is also propelling the market growth. Apart from this, the increasing prominence of counseling and sex therapies to address any emotional or psychological issues contributing to ED and improve overall sexual function and satisfaction is expected to drive the global erectile dysfunction market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the erectile dysfunction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for erectile dysfunction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the erectile dysfunction market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the erectile dysfunction market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the erectile dysfunction market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current erectile dysfunction marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the erectile dysfunction market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the erectile dysfunction market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the erectile dysfunction market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of erectile dysfunction across the seven major markets?
What is the number of prevalent cases (2018-2034) of erectile dysfunction by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of erectile dysfunction by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of erectile dysfunction by type across the seven major markets?
How many patients are diagnosed (2018-2034) with erectile dysfunction across the seven major markets?
What is the size of the erectile dysfunction patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of erectile dysfunction?
What will be the growth rate of patients across the seven major markets?

Erectile Dysfunction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for erectile dysfunction drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the erectile dysfunction market?
What are the key regulatory events related to the erectile dysfunction market?
What is the structure of clinical trial landscape by status related to the erectile dysfunction market?
What is the structure of clinical trial landscape by phase related to the erectile dysfunction market?
What is the structure of clinical trial landscape by route of administration related to the erectile dysfunction market?

ページTOPに戻る

Table of Contents

​1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Erectile Dysfunction - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Erectile Dysfunction - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Erectile Dysfunction - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Erectile Dysfunction - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Erectile Dysfunction - Unmet Needs

10 Erectile Dysfunction - Key Endpoints of Treatment

11 Erectile Dysfunction - Marketed Products
11.1 List of Erectile Dysfunction Marketed Drugs Across the Top 7 Markets
11.1.1 Stendra (Avanafil) – VIVUS
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Caverject (Alprostadil) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Viagra (Sildenafil) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Cialis (Tadalafil) – Eli Lilly and Company
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Levitra (Vardenafil) - Bayer
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Erectile Dysfunction - Pipeline Drugs
12.1 List of Erectile dysfunction Pipeline Drugs Across the Top 7 Markets
12.1.1 TPN 171H - Vigonvita Life Sciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 IPED 2015 - Initiator Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 MED3000 - Futura Medical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Cellgram ED - Pharmicell
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Erectile Dysfunction - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Erectile Dysfunction – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Erectile Dysfunction - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Erectile Dysfunction - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Erectile Dysfunction - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Erectile Dysfunction - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Erectile Dysfunction - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Erectile Dysfunction - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Erectile Dysfunction - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Erectile Dysfunction - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Erectile Dysfunction - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Erectile Dysfunction - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Erectile Dysfunction - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Erectile Dysfunction - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Erectile Dysfunction - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Erectile Dysfunction - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Erectile Dysfunction - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Erectile Dysfunction - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Erectile Dysfunction - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Erectile Dysfunction - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Erectile Dysfunction - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Erectile Dysfunction - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Erectile Dysfunction - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Erectile Dysfunction - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Erectile Dysfunction - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Erectile Dysfunction - Access and Reimbursement Overview

16 Erectile Dysfunction - Recent Events and Inputs From Key Opinion Leaders

17 Erectile Dysfunction Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Erectile Dysfunction Market – Strategic Recommendations

19 Appendix